Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Idelalisib
Cat. No.:
OB0225LY-0380
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR.
Size:
Product Overview
Description:
Idelalisib is a selective phosphatidylinositol-3-kinase δ (PI3Kδ) inhibitor.
Synonym:
GS-1101; CAL-101; 870281-82-6; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; (S)-2-(1-(9H-Purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
CAS No.:
870281-82-6
Compound CID:
11625818
Formula:
C22H18FN7O
Formula Weight:
415.42
Specification
Relative Density:
1.47 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Idelalisib can be used in cancer biology research to explore its mechanism of inhibiting tumor cell proliferation and survival or play an important role in immunology research.
Library Information
Targets:
PI3K family
Receptors:
p110γ; p110δ; PI3K
Pathways:
Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-5
Plate Location:
h5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 120.36 mM
Ethanol Max Solubility:
22 mg/mL; 53 mM
ALogP:
3.624
HBA_Count:
5
HBD_Count:
2
Rotatable Bond:
5
